Precision medicine relies on the identification of biomarkers and genetic variations associated with specific diseases and drug responses. Pharmaceutical R&D departments play a crucial role in discovering and validating these factors, as well as understanding the underlying mechanisms that drive individual variations in drug efficacy and safety.
The development of targeted therapies tailored to individual patients means R&D groups are no longer just responsible for identifying disease pathway targets and optimising drug candidates but are also responsible for identifying and understanding genetic pathways associated with disease. In addition, R&D groups are responsible for conducting specialised pre-clinical/clinical trials designed to assess efficacy and safety of both treatments and vector delivery methods in specific patient populations.
Synthetic biology has also become a critical part of the development lifecycle in areas such as cancer research and cell and gene therapies. It offers powerful tools for engineering and manipulating biological systems, allowing researchers to design and construct customised therapeutic agents with enhanced precision and functionality while enabling the development of novel approaches for target therapies.
But how can pharmaceutical R&D departments accelerate the development of personalised therapies tailored to individual patients’ genetic profiles and disease characteristics?
Laboratory information management systems are essential to precision medicine because they perform vital functions of
streamlining data management, integrating laboratory processes, and facilitating the efficient analyses of patient-specific information. A LIMS enables seamless tracking and management of patient samples, genomic data, and clinical information, enhancing the accuracy and speed of diagnostic testing, treatment selection, and therapeutic monitoring in personalised medicine approaches.
These benefits can be further enhanced by seamlessly integrating a semantic search engine with LIMS, a synthetic biology platform, and an ELN to unlock the full potential of your data. This has three significant benefits for R&D in the realm of precision medicine:
We’ll dive deeper into semantic search and its benefits in an upcoming blog post. For now, let’s focus on how this seamless integration eliminates the barriers that may be holding you back.
The three advantages detailed above are beneficial in and of themselves because they streamline the pharma R&D lifecycle. In addition, they deliver added value by helping you move beyond common challenges like these:
LabVantage integration streamlines precision medicine workflows, reduces manual data retrieval and analysis, and enhances research efficiency. As a result, you can focus more on generating insights and developing innovative therapies and spend less time searching for and managing data.
A single system also allows for greater resource optimisation by integrating multiple fragmented information silos, eliminating redundant data storage, improving data accessibility, and maximising the value of existing infrastructure. This leads to cost savings and more efficient resource allocation.
Product Update Note! LabVantage is currently developing a Synthetic Biology suite of tools that will include support for gene engineering including the development of plasmids and vectors and the creation of synthetic biomolecules. By leveraging these tools along with semantic search provided by the LabVantage Biomax system AILANI, pharmaceutical R&D organisations can accelerate the development of personalised therapies tailored to individual patients’ genetic profiles and disease characteristics.
Are you ready to revolutionise your precision medicine R&D? Contact us today to learn more.